Sort
82,697 grants matching “vaccine development”
KSHV Persistence and Pathogenesis
$1,424,082Jae U Jung · University Of Southern California · P01 · FY2014 · CA
BLOOD GROUP ANTIGENS IN HEALTH AND DISEASE
$1,423,877New York Blood Center · P50 · FY2003 · HL
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies
$1,423,746Rong Fan · Yale University · U01 · FY2020 · CA
Tick saliva and its importance for tick feeding and pathogen transmission
$1,423,607Lucas Tirloni · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Stellenbosch University Clinical Trial Unit, Cape Town, South Africa
$1,422,798Mark Fredric Cotton · Stellenbosch University · U01 · FY2009 · AI
Immunity to Pneumonic Tularemia
$1,422,528Catharine Bosio · Niaid Extramural Activities · Z01 · FY2007 · AI
Membrane Remodeling in Viral Infection, Parasite Replication, and Traumatic Brain Injury
$1,422,462Joshua Zimmerberg · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2018 · HD
MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA)
$1,422,337Jeanette Coffin · Midwest Research Institute · N01 · FY2019 · AI
Molecular approaches to understand vector-host and vector-pathogen interactions
$1,421,968Jesus Valenzuela · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Response Therapies for MDR-TB
$1,421,958Ian M Orme · Colorado State University · U01 · FY2009 · AI
PRODUCTION AND TESTING OF A MODIFIED VACCINIA ANKARA (MVA) VACCINE
$1,421,912Harry Kleanthous · Sanofi Pasteur Biologics, Llc · N01 · FY2015 · AI
HIV/AIDS Clinical Trial Unit in NCAIDS, China CDC
$1,421,642Yiming Shao · National Center For Aids/Std Control And Prevention · U01 · FY2010 · AI
A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
$1,421,482David M. Margolis · Univ Of North Carolina Chapel Hill · U01 · FY2015 · AI
Comprehensive SDSU-UCSD Cancer Center Partnership (2 of 2)
$1,421,400Ana M Navarro · University Of California, San Diego · U54 · FY2008 · CA
Characterization of Proteomes of Category A Pathogens
$1,421,269Diversa Corporation · U01 · FY2005 · AI
Task X17: Malaria Vaccine Safety and Toxicology Studies
$1,420,651Randi Hornback · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2016 · AI
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,420,391Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Gut Homing Cells in SIV infection
$1,420,339Aftab A. Ansari · Emory University · R01 · FY2016 · AI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination
$1,420,303Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Genomic profiling of influenza infections to identify biomarkers of disease severity
$1,420,176Elodie Ghedin · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Virus-Host Interactions: Induction and Evasion of Host Innate Immunity
$1,419,779Sonja Best · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
NOVEL HIV VACCINES
$1,419,348University Of Md Biotechnology Institute · P01 · FY2001 · AI
Viral Diversity and Pathogenesis of Mucosal Gastrointestinal and Respiratory Infections
$1,419,226Robert L. Atmar · Baylor College Of Medicine · U19 · FY2024 · AI
HUMAN MELANOMA--ETIOLOGY, PROGRESSION AND THERAPY
$1,418,371Wistar Institute · P01 · FY2003 · CA
Drivers of individual variation in influenza vaccine response and protection from infection
$1,417,855Sarah Cobey · University Of Chicago · R01 · FY2024 · AI